At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 49 enrolled
Drug / intervention
ruxolitinib creamdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-Label, Single-Arm Study to Evaluate the Effect of Ruxolitinib 1.5% Cream on Itch in Adult Participants With Atopic Dermatitis
In Brief
A Phase 2 clinical trial evaluating ruxolitinib cream for Atopic Dermatitis. Completed, enrolled 49 participants across 2 sites.
Detailed Summary
The purpose of the study is to evaluate the effect of ruxolitinib cream on itch in participants with Atopic Dermatitis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAtopic Dermatitis
CountriesCanada
Collaborators--
Timeline
Phase 2CompletedFinished
20222023202420252026
First PostedApr 2021
Enrollment StartOct 2021
Primary CompletionNov 2022
TodayJul 2026
First PostedApr 9, 2021
Enrollment StartOct 12, 2021
Primary CompletionNov 18, 2022
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 5.2 years ago
Interventions
ruxolitinib creamdrug
ruxolitinib cream 1.5% will be applied twice daily as a thin film